Tim W.’s Post

Personal shoutout to the folks at Intra-Cellular Therapies who just announced a $132 per share buyout offer from Johnson & Johnson Livingston Securities played a small but important role as a part of the syndicate for the company's #directlisting - At the time, it was an innovative way to go public - proving that the traditional VC/IPO path isn't the only way to get listed on the Nasdaq. Important products & therapies came to market, patient investors were rewarded, and significant wealth was created, and this announcement is a vindication for #entrepreneurs and #financial professionals who try to think outside the box. #innovation #betterhealthcarecheaper #mentalhealth #wellness #neurotech #directlisting #publicmarkets #biotechmergers #intracellular #johnsonandjohnson NYSE Forbes BiotechNews & Life Sciences

Blackstone has so far reeled in $1.6 billion for its new life sciences fund, the alternative asset manager said during earnings on Thursday. Nicholas Galakatos and his life sciences team have a target of at least $5 billion for the fund, or the size of its 2020 raise, Blackstone president Jon Gray said on the earnings call. Blackstone bought Galakatos' investment firm Clarus in 2018. They've since done deals with Alnylam, Moderna, Uniquity Bio, Anthos Therapeutics, Autolus, Sanofi and drug developers. #blackstone #blackstonelifesciences #lifesciencesinvesting #biotechinvesting

Blackstone has so far reeled in $1.6 billion for its new life sciences fund, the alternative asset manager said during earnings on Thursday. Nicholas Galakatos and his life sciences team have a target of at least $5 billion for the fund.

A cross-border Latham team led by London corporate partners Robbie McLaren and Maarten Overmars, with associates Samantha Peacock and Antonina Semyachkova, advised BC Partners, a leading international investment firm, on its agreement to sell a majority stake in Synthon to Goldman Sachs Alternatives. The deal represents the latest high-profile transaction on which the firm’s London office has advised during an incredibly busy end to 2024. https://lw.link/LuYSpH

🧐 Did you know that private equity firms can drastically impact stock performance? Akoya Biosciences, Inc. (NASDAQ: AKYA) recently saw its stock soar 18% in a single week, making its biggest winners the private equity firms holding significant stakes. This highlights the influential role of private equity in the market and the potential for substantial returns when firms back innovative companies like Akoya. 📈 💡 With private equity shaping the future of companies, could this be the next big trend in biotech investments? 👉 What are your thoughts on private equity’s influence on stock performance? Share your insights below!

the ASX's future growth is likely to be powered from the current crop of small to mid cap companies entering growth phase. The The Australian Financial Review takes a look at some including Vysarn and Capitol Health Limited. We would add some biotech on the list including PolyNovo Limited, Race Oncology, CLINUVEL PHARMACEUTICALS LTD and of course Pro Medicus Limited #capitalmarkets #asxnews #investorrelations #bourse #biotech #smallcaps #equities #investing

Hyderabad, India, and Singapore-based Aragen Life Sciences has announced a $100 million investment from Quadria Capital, an Asia-focused healthcare private equity firm. #AragenLifeSciences #investment #QuadriaCapital #healthcareprivateequityfirm #privateequityfirm #pharmanews #pharmamanufacturing https://lnkd.in/daaT-NBc

#FundManagerNews 🗞 Merck Mercuriadis, founder of Hipgnosis Song Management, will step down as chair following Blackstone's acquisition of Hipgnosis Songs Fund, which has received unanimous shareholder approval. Read further 👉https://lnkd.in/gRWbCtGx If this affects you and you’d like to discuss our opinion on this fund and how it may or may not continue to fit your investment goals or risk tolerance, please call us on 01420 83517 or email [email protected] #fundmanagement#investments#investing

Public listing? For a life sciences company? Current estimates suggest it costs anywhere between US$1 – 2 billion to bring a drug to market. It’s often because of the huge funding requirements that many life sciences companies turn to public markets to raise capital. Listing is not the ‘easy option’ but for the right companies it may be the most appropriate channel to raise money. In the final article of our ‘DNA of a Life Science Deal’ series, partners Fiona McFarlane and James Baillieu examine why a life sciences company might want to go public, the types of companies that are best suited to life on the public markets and what the process of listing and completing secondary fundraisings looks like. Click here to read more: https://2bird.ly/3OxPHSl #twobirds #ECM #lifesciences #IPO #publicmarkets

Public listing? For a life sciences company? Current estimates suggest it costs anywhere between US$1 – 2 billion to bring a drug to market. It’s often because of the huge funding requirements that many life sciences companies turn to public markets to raise capital. Listing is not the ‘easy option’ but for the right companies it may be the most appropriate channel to raise money. In the final article of our ‘DNA of a Life Science Deal’ series, my colleague Fiona McFarlane and I examine why a life sciences company might want to go public, the types of companies that are best suited to life on the public markets and what the process of listing and completing secondary fundraisings looks like. Click here to read more: https://2bird.ly/3OxPHSl #twobirds #ECM #lifesciences #IPO #publicmarkets